Company profile · free preview

MRNA

MRNA · Updated 10/23/2026

Revenue

$1.9B

Fiscal 2025

Net income

(2.8B)

Fiscal 2025

Free cash flow

(2.1B)

Fiscal 2025

Net cash / (debt)

—

Fiscal 2025

Five-year financials

Fiscal year20252024202320222021
Revenue$1.9B$3.2B$6.8B$19.3B$18.5B
Net income(2.8B)(3.6B)(4.7B)$8.4B$12.2B
Diluted EPS—————
Operating cash flow(1.9B)(3.0B)(3.1B)$5.0B$13.6B
Free cash flow(2.1B)(4.1B)(3.8B)$4.6B$13.3B
Cash$2.6B$1.9B$2.9B$3.2B$6.8B
Total debt—————

Where the cash went

Cumulative, fiscal 2021–2025, straight from the reported cash-flow statements.

Reinvested in capex

24.8%

of operating cash flow

Returned to owners

—

of free cash flow (buybacks + dividends)

Diluted share count

—

change 2021–2025

Capital expenditure $2.6BBar width = share of $10.6B operating cash flow
Operating cash flow$10.6B
Capital expenditure($2.6B)
Free cash flow$8.0B
Share buybacks—
Dividends paid—
Acquisitions (net)—
Net debt issued / (repaid)—
Stock-based compensation (non-cash)—

"—" means a year didn't report that line, so no total is shown rather than an estimate.

SEC filings

  • 10-K · period 2025-12-312026-02-20EDGAR

Ask anything about MRNA's filings

"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.

Start researching free

More companies